In this regard, co‐delivery of DOX and Fidarestat has been shown to lower the MDR1, MRP1 and ABCG2 drug transporters, thereby reducing the drug efflux in tumour cells and decreasing the drug resistance.100. This evidence concerns the gene ABCB1 and neoplasm.